New combo therapy offers hope for Tough-to-Treat leukemia
NCT ID NCT04975919
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study tests a combination of two drugs, venetoclax and decitabine, in 20 adults with acute myeloid leukemia that has returned or not responded to prior treatment. The goal is to see if the combination can shrink or control the cancer. Participants will take the drugs by mouth for 10 days each cycle. The study tracks how many patients achieve remission and monitors side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to wake up immune system against Hard-to-Treat leukemia
- New drug combo aims to outsmart resistant leukemia
- Gentler chemo approach shows promise for tough blood cancers in older patients
- Selective immune cell removal may tame transplant complications
- Promising combo for IDH1 leukemia hits early snag – trial stopped
- Engineered immune cells take aim at Hard-to-Treat leukemia